We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

Main Page

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 62: Line 62:
<table width='100%' style="padding: 10px; background-color: #d7d8f9; font-size: 1.5em;"><tr>
<table width='100%' style="padding: 10px; background-color: #d7d8f9; font-size: 1.5em;"><tr>
<td>[[Proteopedia:About|About]]</td>
<td>[[Proteopedia:About|About]]</td>
-
<td>{{Template:Contact}}</td>
+
<td>[http://proteopedia.org/cgi-bin/contact Contact]</td>
<td>[[Proteopedia:Table of Contents|Table of Contents]]</td>
<td>[[Proteopedia:Table of Contents|Table of Contents]]</td>
<td>[[Proteopedia:Structure Index|Structure Index]]</td>
<td>[[Proteopedia:Structure Index|Structure Index]]</td>

Revision as of 09:09, 21 October 2018

ISSN 2310-6301

As life is more than 2D, Proteopedia helps to bridge the 3D relationships between function & structure of biomacromolecules


Selected Pages Art on Science Journals Education
About this image
Self-assembling Nano-Cages

Huddy, Hsia, Kibler, Xu & 27 others in the Nobel Prize winning group of David Baker have designed standardized protein building blocks that self assemble into a wide range of nanostructures. The building blocks attach to each other at engineered sites and angles, and come in various sizes.

>>> Get a quick overview! >>>

About this image
Opening a Gate to Human Health

by Alice Clark (PDBe)
In the 1970s, an exciting discovery of a family of medicines was made by the Japanese scientist Satoshi Ōmura. One of these molecules, ivermectin, is shown in this artwork bound in the ligand binding pocket of the Farnesoid X receptor, a protein which helps regulate cholesterol in humans. This structure showed that ivermectin induced transcriptional activity of FXR and could be used to regulate metabolism.

>>> Visit this page >>>

About this image
Interconversion of the specificities of human lysosomal enzymes associated with Fabry and Schindler diseases.

IB Tomasic, MC Metcalf, AI Guce, NE Clark, SC Garman. J. Biol. Chem. 2010 doi: 10.1074/jbc.M110.118588
The human lysosomal enzymes α-galactosidase and α-N-acetylgalactosaminidase share 46% amino acid sequence identity and have similar folds. Using a rational protein engineering approach, we interconverted the enzymatic specificity of α-GAL and α-NAGAL. The engineered α-GAL retains the antigenicity but has acquired the enzymatic specificity of α-NAGAL. Conversely, the engineered α-NAGAL retains the antigenicity but has acquired the enzymatic specificity of the α-GAL enzyme. Comparison of the crystal structures of the designed enzyme to the wild-type enzymes shows that active sites superimpose well, indicating success of the rational design. The designed enzymes might be useful as non-immunogenic alternatives in enzyme replacement therapy for treatment of lysosomal storage disorders such as Fabry disease.

>>> Visit this I3DC complement >>>

About this image
You Are What You Eat!

Above is an integral membrane protein that takes up, into your intestinal cells, orally consumed peptide nutrients and drugs. Its lumen-face (top) opens and binds peptide or drug (small solid object in the center), then closes, while its cytoplasmic face (bottom) opens to release its cargo into the intestinal cell, which passes it on to the blood circulation.

>>> See more animations and explanation >>>

How to add content to Proteopedia

Video Guides

Who knows ...

List of Art on Science pages in Proteopedia

What is an Interactive 3D Complement (I3DC)?

List of I3DCs

How to get an I3DC for your paper

Teaching Strategies Using Proteopedia

Examples of Pages for Teaching

How to add content to Proteopedia

About Contact Table of Contents Structure Index Help

Proteopedia Page Contributors and Editors (what is this?)

Joel L. Sussman, Jaime Prilusky

Personal tools